{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T07:15:33Z","timestamp":1792048533043,"version":"4.4.0"},"reference-count":28,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2015,2,9]],"date-time":"2015-02-09T00:00:00Z","timestamp":1423440000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Endocrinology"],"published-print":{"date-parts":[[2015,7]]},"abstract":"<jats:title>Summary<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>Treatment of growth hormone (<jats:styled-content style=\"fixed-case\">GH<\/jats:styled-content>)\u2010deficient adults with <jats:styled-content style=\"fixed-case\">GH<\/jats:styled-content> has been shown to improve a range of metabolic abnormalities and enhance quality of life. However, the results of access to nationally funded treatment have not been reported.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design<\/jats:title><jats:p>Retrospective case series auditing nationally funded treatment of defined <jats:styled-content style=\"fixed-case\">GH<\/jats:styled-content>\u2010deficient adults in New Zealand, with carefully designed entry and exit criteria overseen by a panel of endocrinologists.<\/jats:p><\/jats:sec><jats:sec><jats:title>Patients<\/jats:title><jats:p>Applications for 201 patients were assessed and 191 approved for funded treatment over the initial 3\u00a0years since inception. The majority had <jats:styled-content style=\"fixed-case\">GH<\/jats:styled-content> deficiency following treatment of pituitary adenomas or tumours adjacent to the pituitary.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>After an initial 9\u2010month treatment period using serum <jats:styled-content style=\"fixed-case\">IGF<\/jats:styled-content>\u2010I measurements to adjust <jats:styled-content style=\"fixed-case\">GH<\/jats:styled-content> dosing, all patients reported a significant improvement in quality of life (QoL) score on the QoL\u2010<jats:styled-content style=\"fixed-case\">AGHDA<\/jats:styled-content><jats:sup>\u00ae<\/jats:sup> instrument (baseline (95%<jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>) 19 (18\u201321), 9\u00a0months 6 (5\u20137\u00b75)), and mean serum <jats:styled-content style=\"fixed-case\">IGF<\/jats:styled-content>\u2010I <jats:styled-content style=\"fixed-case\">SD<\/jats:styled-content> scores rose from \u20103 to zero. Mean waist circumference decreased significantly by 2\u00b78\u00a0\u00b1\u00a00\u00b76\u00a0cm. The mean maintenance <jats:styled-content style=\"fixed-case\">GH<\/jats:styled-content> dose after 9\u00a0months of treatment was 0\u00b739\u00a0mg\/day. After 3\u00a0years, 17% of patients had stopped treatment, and all of the remaining patients maintained the improvements seen at 9\u00a0months of treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Carefully designed access to nationally funded <jats:styled-content style=\"fixed-case\">GH<\/jats:styled-content> replacement in <jats:styled-content style=\"fixed-case\">GH<\/jats:styled-content>\u2010deficient adults was associated with a significant improvement in quality of life over a 3\u2010year period with mean daily <jats:styled-content style=\"fixed-case\">GH<\/jats:styled-content> doses lower than in the majority of previously reported studies.<\/jats:p><\/jats:sec>","DOI":"10.1111\/cen.12691","type":"journal-article","created":{"date-parts":[[2014,12,19]],"date-time":"2014-12-19T12:24:25Z","timestamp":1418991865000},"page":"85-90","source":"Crossref","is-referenced-by-count":17,"title":["Three\u2010year experience with access to nationally funded growth hormone (<scp>GH<\/scp>) replacement for <scp>GH<\/scp>\u2010deficient adults"],"prefix":"10.1111","volume":"83","author":[{"given":"I.M.","family":"Holdaway","sequence":"first","affiliation":[{"name":"Department of Endocrinology Auckland Hospital and Greenlane Clinical Centre Auckland New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Hunt","sequence":"additional","affiliation":[{"name":"Department of Endocrinology Christchurch Hospital Christchurch New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Manning","sequence":"additional","affiliation":[{"name":"Department of Endocrinology Dunedin Hospital Dunedin New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Cutfield","sequence":"additional","affiliation":[{"name":"Liggins Institute Auckland University School of Medicine Auckland New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Gamble","sequence":"additional","affiliation":[{"name":"Department of Medicine University of Auckland School of Medicine Auckland New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Ninow","sequence":"additional","affiliation":[{"name":"Pharmaceutical Management Agency Wellington New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Staples\u2010Moon","sequence":"additional","affiliation":[{"name":"Pharmaceutical Management Agency Wellington New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Moodie","sequence":"additional","affiliation":[{"name":"Pharmaceutical Management Agency Wellington New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Metcalfe","sequence":"additional","affiliation":[{"name":"Pharmaceutical Management Agency Wellington New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,2,9]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198912283212605"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1992.tb02347.x"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-09-0258"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2003-030346"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.82.1.82"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2008-1538"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2003-030134"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.1999.00695.x"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1530\/eje.1.02179"},{"issue":"9","key":"e_1_2_6_11_1","first-page":"2","article-title":"Hypopituitary control and complications study (HypoCCS): a decade of an outcomes assessment and observations study","volume":"31","author":"Lamberts S.W.","year":"2008","journal-title":"Journal of Endocrinological Investigation"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2003-030840"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-4012"},{"issue":"19","key":"e_1_2_6_14_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta6190","article-title":"Clinical effectiveness and cost\u2010effectiveness of growth hormone in adults in relation to impact on quality of life: a systematic review and economic evaluation","volume":"6","author":"Bryant J.","year":"2002","journal-title":"Health Technology Assessment"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.87.5.8509"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2009-0299"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008987922774"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/14.6.540"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-0179"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-07-0631"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-09-0319"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2012.9"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-1995"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-2415"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-1215"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.87.5.8482"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ghir.2005.06.018"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60673-4"},{"key":"e_1_2_6_29_1","first-page":"9","article-title":"Assessment of quality of life in adult patients with GH deficiency: KIMS contribution to clinical practice and pharmacoeconomic evaluations","volume":"157","author":"Koltowska\u2010Haggstrom M.","year":"2007","journal-title":"European Journal of Endocrinology"}],"container-title":["Clinical Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fcen.12691","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cen.12691","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T19:17:41Z","timestamp":1695496661000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/cen.12691"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2,9]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,7]]}},"alternative-id":["10.1111\/cen.12691"],"URL":"https:\/\/doi.org\/10.1111\/cen.12691","archive":["Portico"],"relation":{},"ISSN":["0300-0664","1365-2265"],"issn-type":[{"value":"0300-0664","type":"print"},{"value":"1365-2265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,2,9]]}}}